The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease

Cellular and Molecular Immunology

Volumn 7, Issue 3, 2010, Pages 182-189

  Leung, Stewart ^a   Liu, Xuebin ^a   Fang, Lei ^a   Chen, Xi ^a   Guo, Taylor ^a   Zhang, Jingwu ^a  

^a GLAXOSMITHKLINE   (China)

Author keywords

Autoimmune disease; Cytokine; Regulatory T cell; T helper 17 cell

Indexed keywords

ADALIMUMAB; AMG 108; APILIMOD; ATACICEPT; BRIAKINUMAB; CD39 ANTIGEN; CD4 ANTIGEN; DACLIZUMAB; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 7; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; CYTOKINE;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CROHN DISEASE; CYTOKINE PRODUCTION; DOWN REGULATION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; UPREGULATION; ANIMAL; CYTOLOGY; HELPER CELL; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; INTERLEUKIN-17; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 77953255484     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2010.22     Document Type: Review

References (128)

1. H2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173. (Pubitemid 19138011)
2. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32-46. (Pubitemid 46365005)
3. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-1141. (Pubitemid 41541791)
4. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562. (Pubitemid 38680433)
5. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-1132. (Pubitemid 41541790)
6. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177:566-573. (Pubitemid 43939170)
7. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-852. (Pubitemid 46697925)
8. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB-and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004;6: R120-R128.
9. Corthay A. How do regulatory T cells work? Scand J Immunol 2009;70:326-336.
10. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747. (Pubitemid 40563183)
11. Billiau A, Heremans H, Vandekerckhove F, Dijkmans R, Sobis H, Meulepas E et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988;140:1506-1510.
12. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA et al. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-1957. (Pubitemid 38032126)
13. + Tregs. J Clin Invest 2006;116:2434-2441. (Pubitemid 44330142)
14. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517.
15. Steinman L. A rush to judgment on Th17. J Exp Med 2008;205:1517-1522. (Pubitemid 351962013)
16. - T lymphocytes. J Immunol 1981;127:1420-1423. (Pubitemid 11021014)
17. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009;183:7169-7177.
18. Liu X, Leung S, Wang C, Tan Z, Wang J, Guo TB et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med 16:191-197.
19. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
20. Stummvoll GH, DiPaolo RJ, Huter EN, Davidson TS, Glass D, Ward JM et al. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 2008;181:1908-1916.
21. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886. (Pubitemid 38032120)
22. + regulatory T cells rescue scurfy mice. Eur J Immunol 2008;38:1814-1821.
23. + regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009;183:7602-7610.
24. + T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006;180:178-184. (Pubitemid 44767710)
25. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-979. (Pubitemid 38481088)
26. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007;13:423-431. (Pubitemid 46559831)
27. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277-285. (Pubitemid 39031247)
28. hi T-regulatory cells. Blood 2006;108:253-261. (Pubitemid 43990636)
29. + T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003;33:215-223. (Pubitemid 36157659)
30. + regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004;6: R335-R346.
31. + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005;140:360-367. (Pubitemid 40559165)
32. + regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004;50:2775-2785. (Pubitemid 39209514)
33. + regulatory T cells through IL-7 signaling pathway. J Immunol 2009;183:6135-6144.
34. H2 model: a personal perspective. Nat Immunol 2006;7:539-541. (Pubitemid 43797329)
35. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today 2000;21:479-483.
36. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-669.
37. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357. (Pubitemid 16136806)
38. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-596. (Pubitemid 27511769)
39. H17 and regulatory T cells. Nature 2006;441:235-238.
40. + T cells prevents development of experimental autoimmune diseases. J Immunol 2008;180:6070-6076.
41. Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008;105:9041-9046.
42. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007;282:9358-9363. (Pubitemid 47104613)
43. + T helper cells. Cell 2006;126:1121-1133. (Pubitemid 44380299)
44. H17 cell differentiation by antagonizing RORgammat function. Nature 2008;453:236-240. (Pubitemid 351667978)
45. Aggarwal S, Ghilardi N, Xie MH, De Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-1914. (Pubitemid 36801431)
46. De Jong BA, Huizinga TW, Bollen EL, Uitdehaag BM, Bosma GP, van Buchem MA et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002;126:172-179. (Pubitemid 34521742)
47. H17 cells. Nature 2007;448:484-487. (Pubitemid 47123515)
48. H17 cells. Nature 2008;454:350-352.
49. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009;30:576-587.
50. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-949. (Pubitemid 47300008)
51. Shirakawa F, Tanaka Y, Ota T, Suzuki H, Eto S, Yamashita U. Expression of interleukin 1 receptors on human peripheral T cells. J Immunol 1987;138:4243-4248. (Pubitemid 17090393)
52. Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008;181:5948-5955.
53. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009;10:314-324.
54. Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006;176:5652-5661.
55. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007;39:1083-1091. (Pubitemid 47340652)
56. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-862. (Pubitemid 47347319)
57. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007;39:1108-1113. (Pubitemid 47340654)
58. Palmer MJ, Mahajan VS, Trajman LC, Irvine DJ, Lauffenburger DA, Chen J. Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol 2008;5:79-89.
59. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008;205:1701-1714. (Pubitemid 351962032)
60. Liu X, Leung S, Wang C, Tan Z, Wang J, Guo TB et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med 2010;16:191-197.
61. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061. (Pubitemid 36222930)
62. + T regulatory cells. Nat Immunol 2003;4:337-342. (Pubitemid 36432315)
63. + regulatory T cells. Nat Immunol 2003;4:330-336. (Pubitemid 36432314)
64. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000;106: R75-81. (Pubitemid 32038594)
65. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20. (Pubitemid 32044512)
66. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73. (Pubitemid 32044521)
67. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-21. (Pubitemid 32044513)
68. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 2005;102:5126-5131.
69. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329-341. (Pubitemid 40387475)
70. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431-440.
71. +251 immunoregulatory T cells. J Exp Med 2001;194:427-438. (Pubitemid 32835039)
72. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005;6:152-162. (Pubitemid 40268196)
73. Soper DM, Kasprowicz DJ, Ziegler SF. IL-2Rbeta links IL-2R signaling with Foxp3 expression. Eur J Immunol 2007;37:1817-1826. (Pubitemid 47071667)
74. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 2008;28:100-111.
75. + T regulatory cell development during the neonatal period. J Exp Med 2005;201:769-777. (Pubitemid 40403028)
76. + T regulatory cells. J Immunol 2008;181:225-234.
77. + regulatory T cell development. J Immunol 2008;181:3285-3290.
78. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-1151. (Pubitemid 41541792)
79. + regulatory T cells. J Immunol 2007;178:280-290. (Pubitemid 46033611)
80. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007;109:4368-4375. (Pubitemid 46743405)
81. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008;29:44-56.
82. + regulatory T cells: more of the same or a division of labor? Immunity 2009;30:626-635.
83. + T cell lineage differentiation. Immunity 2009;30:646-655.
84. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced Treg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007;204:1765-1774. (Pubitemid 47236315)
85. hi cells. Immunity 2008;29:758-770.
86. H17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007;317:256-260. (Pubitemid 47076203)
87. + regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007;204:1757-1764. (Pubitemid 47236314)
88. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007;204:1775-1785. (Pubitemid 47236316)
89. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009;10:1000-1007.
90. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009;10:595-602.
91. H2 responses. Nature 2009;458:351-356.
92. H17 responses in a Stat3-dependent manner. Science 2009;326:986-991.
93. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296. (Pubitemid 28357757)
94. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-569. (Pubitemid 350190247)
95. + T cells. Blood 2007;109:2058-2065. (Pubitemid 46348206)
96. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004;21:589-601. (Pubitemid 39370513)
97. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005;174:1783-1786. (Pubitemid 40223916)
98. + regulatory T cell function. Science 2008;322:271-275.
99. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-1232. (Pubitemid 47281420)
100. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-1265. (Pubitemid 46919862)
101. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999;190:995-1004.
102. + T cells. J Autoimmun 2001;16:115-123. (Pubitemid 32552986)
103. + regulatory T cells. Int Immunol 2004;16:249-256. (Pubitemid 38195655)
104. Burkhart C, Liu GY, Anderton SM, Metzler B, Wraith DC. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol 1999;11:1625-1634. (Pubitemid 29481729)
105. + T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003;100:10878-10883. (Pubitemid 37140121)
106. Fantini MC, Rizzo A, Fina D, Caruso R, Becker C, Neurath MF et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007;37:3155-3163. (Pubitemid 350131294)
107. + regulatory T cells. Proc Natl Acad Sci USA 2008;105:18460-18465.
108. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-39. (Pubitemid 46148753)
109. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007;26:371-381. (Pubitemid 46413906)
110. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-632.
111. Stubgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008;37:281-292.
112. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006;116:1317-1326.
113. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66:483-489.
114. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007;13:711-718. (Pubitemid 46889754)
115. + regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007;319:41-52. (Pubitemid 46110995)
116. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 2). Lancet 2008;371:1675-1684. (Pubitemid 351671884)
117. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009;84:14-24.
118. Ding C, Xu J, Li J. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs 2008;9:515-522. (Pubitemid 351677906)
119. Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 2009; in press.
120. Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 2007;10:53-59. (Pubitemid 46438284)
121. Waugh J, Perry CM. Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 2005;19:189-202.
122. Steinman L. Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol; 11:41-44.
123. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-553.
124. Dhillon S, Lyseng-Williamson KA, Scott LJ. Etanercept: a review of its use in the management of rheumatoid arthritis. Drugs 2007;67:1211-1241. (Pubitemid 46880983)
125. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-1065. (Pubitemid 38480815)
126. Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732-739. (Pubitemid 46846691)
127. Martin R. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener Dis 2008;5:23-26. (Pubitemid 350261812)
128. Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 2008;9:1216-1227.